

Integrated immune dynamics define correlates of COVID-19

Cell Reports Medicine

2, 100208

DOI: [10.1016/j.xcrm.2021.100208](https://doi.org/10.1016/j.xcrm.2021.100208)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. Clinical and Translational Immunology, 2021, 10, e1258.	1.7	28
3	Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 237-253.	1.1	78
4	Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome. Cell Reports Medicine, 2021, 2, 100269.	3.3	41
6	CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity, 2021, 54, 1066-1082.e5.	6.6	106
7	Adamantiades-Behçet's disease (Behçet's disease) and COVID-19. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e541-e543.	1.3	12
9	Persistence of humoral response upon SARS-CoV-2 infection. Reviews in Medical Virology, 2022, 32, e2272.	3.9	14
11	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Microorganisms, 2021, 9, 1389.	1.6	4
12	SARS-CoV-2-specific CD8 ⁺ T cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. Immunology and Cell Biology, 2021, 99, 990-1000.	1.0	28
13	Anti-COVID-19 measurements for hidradenitis suppurativa patients. Experimental Dermatology, 2021, 30, 18-22.	1.4	12
16	Antibody Responsiveness to Influenza: What Drives It?. Viruses, 2021, 13, 1400.	1.5	5
17	Natural killer cells and unconventional T cells in COVID-19. Current Opinion in Virology, 2021, 49, 176-182.	2.6	28
25	Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. Journal of Biological Chemistry, 2021, 297, 101065.	1.6	20
26	Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 731100.	2.2	32
28	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
30	Impaired HA-specific T follicular helper cell and antibody responses to influenza vaccination are linked to inflammation in humans. ELife, 2021, 10, .	2.8	26
31	Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study. Transplant Infectious Disease, 2021, 23, e13743.	0.7	5
32	T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. Journal of Leukocyte Biology, 2022, 111, 355-365.	1.5	25
33	Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?. Multiple Sclerosis and Related Disorders, 2022, 57, 103416.	0.9	17

#	ARTICLE	IF	CITATIONS
34	Evaluation of Human Circulating T Follicular Helper Cells in Influenza- and SARS-CoV-2-Specific B Cell Immunity. <i>Methods in Molecular Biology</i> , 2022, 2380, 201-209.	0.4	0
35	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. <i>EBioMedicine</i> , 2021, 74, 103729.	2.7	29
36	Adults with <i>Plasmodium falciparum</i> malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children. <i>EBioMedicine</i> , 2022, 75, 103784.	2.7	6
37	Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. <i>BMC Medicine</i> , 2022, 20, 26.	2.3	152
38	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 210-216.	7.0	486
39	Treating COVID-19: Evolving approaches to evidence in a pandemic. <i>Cell Reports Medicine</i> , 2022, 3, 100533.	3.3	7
40	SARS-CoV-2 Induces Cytokine Responses in Human Basophils. <i>Frontiers in Immunology</i> , 2022, 13, 838448.	2.2	11
41	T and B Cells Immune Response and the importance of vaccines Against SARS-CoV-2. <i>Revista Bionatura</i> , 2022, 7, 1-8.	0.1	0
43	Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 11, 100228.	1.5	2
44	Count on us: TÂcells in SARS-CoV-2 infection and vaccination. <i>Cell Reports Medicine</i> , 2022, 3, 100562.	3.3	86
45	Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States. <i>Cells</i> , 2022, 11, 847.	1.8	27
46	Protective and pathogenic role of humoral responses in COVID-19. <i>Journal of Microbiology</i> , 2022, 60, 268-275.	1.3	4
47	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. <i>Nature Immunology</i> , 2022, 23, 768-780.	7.0	41
48	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10
49	Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. <i>Clinical Pharmacokinetics</i> , 2022, 61, 155-165.	1.6	8
50	T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants. <i>Frontiers in Medicine</i> , 2021, 8, 793102.	1.2	21
52	Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil. <i>Journal of Immunology</i> , 2022, , ji2101199.	0.4	6
53	T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4

#	ARTICLE	IF	CITATIONS
54	Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
55	Cytokine response over the course of COVID-19 infection in pregnant women. <i>Cytokine</i> , 2022, 154, 155894.	1.4	9
56	Influence of Advanced Organ Support (ADVOS) on Cytokine Levels in Patients with Acute-on-Chronic Liver Failure (ACLF). <i>Journal of Clinical Medicine</i> , 2022, 11, 2782.	1.0	4
57	Impact of solid organ transplant status on outcomes of hospitalized patients with COVID-19 infection. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	10
58	A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. <i>Cell Reports</i> , 2022, 39, 110815.	2.9	0
59	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. <i>Nature Communications</i> , 2022, 13, 2774.	5.8	21
60	The IL-1 β , IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. <i>Cell Reports Medicine</i> , 2022, 3, 100663.	3.3	175
61	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
62	The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19. <i>Inflammation Research</i> , 2022, 71, 923-947.	1.6	30
63	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. <i>Nature Communications</i> , 2022, 13, .	5.8	42
64	Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	34
65	<scp>TrackSOM</scp>: Mapping immune response dynamics through clustering of time-course cytometry data. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 54-70.	1.1	0
67	Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. <i>ELife</i> , 0, 11, .	2.8	11
69	Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria. <i>PLoS ONE</i> , 2022, 17, e0271382.	1.1	3
70	PD-1 blockade unblocks immune responses to vaccination. <i>Nature Immunology</i> , 2022, 23, 1135-1137.	7.0	2
71	Cardiac megakaryocytes in SARS-CoV-2 positive autopsies. <i>Histopathology</i> , 0, , .	1.6	0
72	Ultrarapid and ultrasensitive detection of SARS-CoV-2 antibodies in COVID-19 patients via a 3D-printed nanomaterial-based biosensing platform. <i>Journal of Medical Virology</i> , 2022, 94, 5808-5826.	2.5	8
74	Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function. <i>European Journal of Pharmacology</i> , 2022, 933, 175267.	1.7	6

#	ARTICLE	IF	CITATIONS
75	IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden. Cytokine, 2022, 159, 156020.	1.4	2
76	Heterogenous CD8+ T Cell Maturation and "Polarization"™ in Acute and Convalescent COVID-19 Patients. Viruses, 2022, 14, 1906.	1.5	16
77	Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients. Cell Death and Disease, 2022, 13, .	2.7	5
78	Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives. Cell Communication and Signaling, 2022, 20, .	2.7	10
79	Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?. PLoS Pathogens, 2022, 18, e1010821.	2.1	7
80	Parallel detection of <scp>SARSâ€CoV</scp>â€2 epitopes reveals dynamic immunodominance profiles of <scp>CD8</scp>⁺ T memory cells in convalescent <scp>COVID</scp>â€19 donors. Clinical and Translational Immunology, 2022, 11, .	1.7	10
81	Ocrelizumab Concentration Is a Good Predictor of <scp>SARSâ€CoV</scp>â€2 Vaccination Response in Patients with Multiple Sclerosis. Annals of Neurology, 2023, 93, 103-108.	2.8	3
82	Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness. Vojnosanitetski Pregled, 2022, 79, 1201-1208.	0.1	0
83	Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory. Scientific Reports, 2022, 12, .	1.6	1
84	Longitudinal single-cell analysis of SARS-CoV-2â€reactive B cells uncovers persistence of early-formed, antigen-specific clones. JCI Insight, 2023, 8, .	2.3	6
86	PD-1highCXCR5â€CD4+ peripheral helper TÂcells promote CXCR3+ plasmablasts in human acute viral infection. Cell Reports, 2023, 42, 111895.	2.9	9
87	Integrative systems immunology uncovers molecular networks of the cell cycle that stratify COVIDâ€19 severity. Journal of Medical Virology, 2023, 95, .	2.5	8
88	Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID. Viruses, 2023, 15, 400.	1.5	27
89	Circulating effector Î³ T cell populations are associated with acute coronavirus disease 19 in unvaccinated individuals. Immunology and Cell Biology, 0, , .	1.0	1
90	Natural killerÂcells in COVID-19: from infection, to vaccination and therapy. Future Virology, 2023, 18, 177-191.	0.9	11
91	Comparative assessment of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2. Profilakticheskaya Meditsina, 2022, 25, 82.	0.2	1
92	Natural killer cells in sepsis: Friends or foes?. Frontiers in Immunology, 0, 14, .	2.2	2
93	Crossâ€sectional analysis reveals autoantibody signatures associated with COVIDâ€19 severity. Journal of Medical Virology, 2023, 95, .	2.5	10

#	ARTICLE	IF	CITATIONS
95	HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. Vaccines, 2023, 11, 548.	2.1	1
96	Robust SARS-CoV-2 T _H cell responses with common TCR α motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Reports Medicine, 2023, 4, 101017.	3.3	7
97	Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and $\gamma\delta$ T cell perturbations. JCI Insight, 2023, 8, .	2.3	4